Soticlestat as add-on therapy investigated for seizure reduction in Dravet and Lennox-Gastaut Syndromes

Severe developmental and epileptic encephalopathies like Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS) are characterized by frequent, drug-resistant seizures and significant cognitive impairment. Current anti-seizure therapies often fail to achieve adequate seizure control, leading to a substantial burden on patients and caregivers. There is an urgent need for novel, effective, and well-tolerated treatments to improve seizure outcomes and quality of life. Soticlestat is being explored as a potential new therapeutic option, targeting a pathway distinct from many existing anti-epileptic drugs, aiming to address this unmet medical need.

This study is designed to assess soticlestat as an add-on therapy in children and adults diagnosed with either Dravet Syndrome or Lennox-Gastaut Syndrome. Participants will continue their existing standard anti-seizure medication regimen. In addition to their baseline therapy, they will receive tablets of soticlestat. The primary objective is to determine if this add-on treatment effectively reduces the overall number of seizures experienced by patients. The study involves scheduled in-person visits and follow-up phone calls to monitor patient progress and safety throughout the trial duration. No specific dose or duration is provided in the abstract.